Agenus to Provide Corporate Update and Q2 2022 Financial Report


Agenus Inc.

Conference call on Tuesday, August 9, 2022 at 8:30 a.m. ET

LEXINGTON, Mass., July 27 10, 2022 (GLOBE NEWSWIRE) — Agenus (NASDAQ:AGEN), an immuno-oncology company with an extensive portfolio of therapeutic products designed to activate the immune response to cancers and infections, today announced the release of its second quarter 2022 financial results before market open on Tuesday, August 9, 2022. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide an update. company day.

Conference call
Phone numbers: (646) 307-1963 (US-NY) or (800) 715-9871 (US & CA)
Event ID: 6683845

A webcast and replay of the conference call will be accessible from the Events and Presentations page of the Company’s website at and via

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that mobilize the body’s immune system to fight cancer and infection. The Company’s vision is to expand patient populations benefiting from cancer immunotherapy by pursuing combined approaches that leverage a broad repertoire of therapeutic antibodies, adoptive cell therapies (through its subsidiary MiNK Therapeutics) and adjuvants (via its subsidiary SaponiQx). The company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capability to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit and our Twitter account @agenus_bio. Information that may be important to investors will be regularly posted on our website and on Twitter.

Agenus Inc.
Ethan Lovell
Head of External Affairs and Communications
[email protected]


Comments are closed.